Compare Stocks: WHWK, GERN, ANNX, and CADL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.57 -2.9%	$4.56	$2.54 ▼ $7.18	$676.23M	1.32	2.96 million shs	846,203 shs
CADL Candel Therapeutics	$8.91 -1.8%	$11.46	$4.35 ▼ $14.00	$682.79M	-0.32	1.45 million shs	399,507 shs
GERN Geron	$1.23 +2.9%	$1.39	$1.04 ▼ $2.01	$787.03M	0.61	13.71 million shs	1.91 million shs
WHWK Whitehawk Therapeutics	$3.05 +2.5%	$4.22	$1.97 ▼ $5.49	$173.03M	0.92	321,525 shs	111,508 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-4.18%	-8.48%	-7.09%	-37.69%	+22.33%
CADL Candel Therapeutics	-2.16%	-7.64%	-15.07%	-4.32%	+56.92%
GERN Geron	-0.83%	-0.83%	-13.14%	-16.20%	-4.03%
WHWK Whitehawk Therapeutics	-1.66%	-12.90%	-27.03%	-23.65%	+50.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$3.57 -2.9%	$4.56	$2.54 ▼ $7.18	$676.23M	1.32	2.96 million shs	846,203 shs
CADL Candel Therapeutics	$8.91 -1.8%	$11.46	$4.35 ▼ $14.00	$682.79M	-0.32	1.45 million shs	399,507 shs
GERN Geron	$1.23 +2.9%	$1.39	$1.04 ▼ $2.01	$787.03M	0.61	13.71 million shs	1.91 million shs
WHWK Whitehawk Therapeutics	$3.05 +2.5%	$4.22	$1.97 ▼ $5.49	$173.03M	0.92	321,525 shs	111,508 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-4.18%	-8.48%	-7.09%	-37.69%	+22.33%
CADL Candel Therapeutics	-2.16%	-7.64%	-15.07%	-4.32%	+56.92%
GERN Geron	-0.83%	-0.83%	-13.14%	-16.20%	-4.03%
WHWK Whitehawk Therapeutics	-1.66%	-12.90%	-27.03%	-23.65%	+50.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.29	317.99% Upside
CADL Candel Therapeutics	2.73	Moderate Buy	$20.14	126.83% Upside
GERN Geron	2.20	Hold	$4.00	226.53% Upside
WHWK Whitehawk Therapeutics	2.75	Moderate Buy	$8.33	176.12% Upside

Current Analyst Ratings Breakdown

Latest WHWK, GERN, ANNX, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/30/2026	WHWK Whitehawk Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$9.00
9/30/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$14.00 ➝ $15.00
9/21/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00
9/2/2026	WHWK Whitehawk Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Underperform ➝ Market Perform
8/13/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$23.00
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
GERN Geron	$183.88M	4.28	N/A	N/A	$0.35 per share	3.50
WHWK Whitehawk Therapeutics	$7.14M	24.10	N/A	N/A	$2.89 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	20.42	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
WHWK Whitehawk Therapeutics	-$20.60M	-$1.12	N/A	N/A	N/A	N/A	-53.89%	-49.97%	N/A

Latest WHWK, GERN, ANNX, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	CADL Candel Therapeutics	-$0.3468	N/A	N/A	N/A	N/A	N/A
11/9/2026	Q3 2026	ANNX Annexon	-$0.28	N/A	N/A	N/A	$3.50 million	N/A
11/4/2026	Q3 2026	GERN Geron	-$0.01	N/A	N/A	N/A	$60.70 million	N/A
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	WHWK Whitehawk Therapeutics	-$0.30	-$0.20	+$0.10	-$0.20	N/A	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
WHWK Whitehawk Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
CADL Candel Therapeutics	0.38	16.09	16.09
GERN Geron	0.55	6.91	5.16
WHWK Whitehawk Therapeutics	N/A	17.38	17.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
CADL Candel Therapeutics	13.93%
GERN Geron	73.71%
WHWK Whitehawk Therapeutics	52.08%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
CADL Candel Therapeutics	14.30%
GERN Geron	1.71%
WHWK Whitehawk Therapeutics	49.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
GERN Geron	258	642.47 million	631.49 million	Optionable
WHWK Whitehawk Therapeutics	23	57.01 million	28.56 million	N/A

WHWK, GERN, ANNX, and CADL Headlines

Recent News About These Companies

Whitehawk Therapeutics (NASDAQ:WHWK) and Surrozen (NASDAQ:SRZN) Critical Comparison

October 14 at 3:59 AM | americanbankingnews.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Target Price of $8.33 According to Brokerages

October 8, 2026 | marketbeat.com

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 As A Durable ADC Target In Ovarian Cancer And Reinforces Scientific Rationale For HWK-016

October 3, 2026 | marketscreener.comM

Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026

October 1, 2026 | prnewswire.com

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Short Interest Update

September 16, 2026 | marketbeat.com

Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Whitehawk Therapeutics: PTK7 Stability Supports ADC Development In EGFR Wild-Type NSCLC

September 14, 2026 | rttnews.com

Whitehawk data support PTK7 target for HWK-007

September 14, 2026 | grafa.comG

Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026

September 13, 2026 | prnewswire.com

Whitehawk Therapeutics Adds Oncology Leader to Board

September 10, 2026 | tipranks.com

Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors

September 10, 2026 | prnewswire.com

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

September 2, 2026 | prnewswire.com

What Makes Whitehawk Therapeutics, Inc. (WHWK) a Strong Momentum Stock: Buy Now?

August 28, 2026 | zacks.com

Wall Street Analysts Predict a 47.64% Upside in Whitehawk Therapeutics, Inc. (WHWK): Here's What You Should Know

August 26, 2026 | zacks.com

Whitehawk Therapeutics Inc WHWK

August 14, 2026 | morningstar.comM

TD Cowen Remains a Hold on Whitehawk Therapeutics (WHWK)

August 10, 2026 | theglobeandmail.com

Whitehawk’s HWK-016 ADC Trial Advances in Tough Ovarian and Endometrial Cancers

August 6, 2026 | tipranks.com

Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

August 6, 2026 | prnewswire.com

Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development

July 7, 2026 | businesswire.com

10 Hot Biotech Stocks Under $5 to Buy

June 10, 2026 | insidermonkey.com

Is Whitehawk Therapeutics (WHWK) One Of The Hot Biotech Stocks Under $5 To Buy?

June 10, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, GERN, ANNX, and CADL Company Descriptions

Annexon NASDAQ:ANNX

$3.56 -0.11 (-2.86%)

As of 12:21 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Candel Therapeutics NASDAQ:CADL

$8.91 -0.16 (-1.74%)

As of 12:21 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Geron NASDAQ:GERN

$1.23 +0.04 (+2.94%)

As of 12:21 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Whitehawk Therapeutics NASDAQ:WHWK

$3.04 +0.08 (+2.53%)

As of 12:20 PM Eastern

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest WHWK, GERN, ANNX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest WHWK, GERN, ANNX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

WHWK, GERN, ANNX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, GERN, ANNX, and CADL Company Descriptions

Annexon NASDAQ:ANNX

Candel Therapeutics NASDAQ:CADL

Geron NASDAQ:GERN

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest WHWK, GERN, ANNX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest WHWK, GERN, ANNX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

WHWK, GERN, ANNX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

WHWK, GERN, ANNX, and CADL Company Descriptions

Annexon NASDAQ:ANNX

Candel Therapeutics NASDAQ:CADL

Geron NASDAQ:GERN

Whitehawk Therapeutics NASDAQ:WHWK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools